Detalhe da pesquisa
1.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Blood
; 143(14): 1399-1413, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194688
2.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
3.
Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach.
Int J Mol Sci
; 25(7)2024 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38612443
4.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Cancer
; 129(7): 992-1004, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692409
5.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
6.
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.
Hematol Oncol
; 41(1): 128-138, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265128
7.
A Leukemic Target with a Thousand Faces: The Mitochondria.
Int J Mol Sci
; 24(17)2023 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37685874
8.
mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells.
Int J Mol Sci
; 24(2)2023 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36674750
9.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363892
10.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137397
11.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739457
12.
Two conserved glycine residues in mammalian and Dictyostelium Rictor are required for mTORC2 activity and integrity.
J Cell Sci
; 132(22)2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31653780
13.
Impact of kidney transplant morbidity on elderly recipients' outcomes.
Aging Clin Exp Res
; 33(3): 625-633, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323169
14.
Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms.
J Cell Mol Med
; 24(18): 10978-10986, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790151
15.
Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe.
Int J Mol Sci
; 21(11)2020 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32486249
16.
Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Int J Mol Sci
; 21(20)2020 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33081324
17.
Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
J Cell Mol Med
; 23(6): 4349-4357, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31033209
18.
A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia.
Haematologica
; 104(4): 717-728, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30409797
19.
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
Int J Mol Sci
; 20(9)2019 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31067725
20.
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 182(5): 701-704, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29984826